tbuckley/cabot-search huggingface dataset:
Expression of Tumor-Associated Antigen (DF3) in Atypical Hyperplasias and In Situ Carcinomas of the Human Breast
Authors: N Ohuchi, D L Page, M J Merino, M J Viglione, D W Kufe, J Schlom
Journal: JNCI Journal of the National Cancer Institute (1987)

The monoclonal antibody (MoAb) DF3 prepared against a membrane-enriched fraction of human breast carcinoma has previously shown a differential reactivity to cytoplasmic antigen in carcinomas versus antigen concentrated on apical borders in benign lesions of the breast. In the present report the cytoplasmic reactivity of MoAb DF3 within a spectrum of benign and malignant breast lesions was studied to define whether the DF3 antigen is expressed in the cytoplasm of potentially premalignant lesions, i.e., atypical hyperplasias, or early malignant lesions, i.e., in situ carcinomas. Biopsy specimens of breast lesions from 108 women, including 28 patients with invasive carcinoma, 12 with in situ carcinoma, 17 with atypical hyperplasia, 25 with proliferative lesions without atypia, and 26 with nonproliferative lesions, were examined for DF3 antigen expression with the use of an indirect immunohistochemical method. Atypical hyperplasias were less reactive with MoAb DF3 than invasive carcinomas (P = .05 by Wilcoxon rank sum test). No significant statistical differences were observed, however, between invasive carcinomas and in situ carcinomas or between in situ carcinomas and atypical hyperplasias on the basis of cytoplasmic DF3 reactivity. Invasive carcinomas, in situ carcinomas, and atypical hyperplasias, however, demonstrated significantly higher reactivity with MoAb DF3 in the cytoplasm than proliferative lesions without atypia and nonproliferative lesions (P less than .01). These studies demonstrate that atypical hyperplasias express elevated levels of a given tumor-associated antigen and thus provide further immunologic evidence that these lesions are premalignant.
Abortion rates stay steady in developing nations but fall elsewhere
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Abortion rates in developing countries have remained relatively unchanged over the last 25 years because of difficulties in accessing effective contraception, whereas they have fallen to a historic low in developed countries, a paper published in the Lancet has shown.1

The paper said that countries with restrictive abortion laws have similar rates to those where it is legal, but the procedure is often performed under unsafe conditions.

The authors used data from nationally representative surveys, official statistics, and other studies—along with information on the level of unmet need for …
Generation of nanovesicles with sliced cellular membrane fragments for exogenous material delivery
Authors: Jaewoong Yoon, Wonju Jo, Dayeong Jeong, Junho Kim, Hwapyeong Jeong, Jaesung Park
Journal: Biomaterials (2015)

We propose a microfluidic system that generates nanovesicles (NVs) by slicing living cell membrane with microfabricated 500 nm-thick silicon nitride (SixNy) blades. Living cells were sliced by the blades while flowing through microchannels lined with the blades. Plasma membrane fragments sliced from the cells self-assembled into spherical NVs of ~100-300 nm in diameter. During self-assembly, the plasma membrane fragments enveloped exogenous materials (here, polystyrene latex beads) from the buffer solution. About 30% of beads were encapsulated in NVs, and the generated NVs delivered the encapsulated beads across the plasma membrane of recipient cells, but bare beads could not penetrate the plasma membrane of recipient cells. This result implicates that the NVs generated using the method in this study can encapsulate and deliver exogenous materials to recipient cells, whereas exosomes secreted by cells can deliver only endogenous cellular materials.
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism
Authors: Ryan Flynn, Katelyn Paz, Jing Du, Dawn K. Reichenbach, Patricia A. Taylor, Angela Panoskaltsis-Mortari, Ante Vulic, Leo Luznik, Kelli K. P. MacDonald, Geoffrey R. Hill, Melanie S. Nyuydzefe, Jonathan M. Weiss, Wei Chen, Alissa Trzeciak, Jon S. Serody, Ethan G. Aguilar, William J. Murphy, Ivan Maillard, David Munn, John Koreth, Corey S. Cutler, Joseph H. Antin, Jerome Ritz, Samuel D. Waksal, Alexandra Zanin-Zhorov, Bruce R. Blazar
Journal: Blood (2016)
All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors
Authors: K Mihara, T Yoshida, S Ishida, Y Takei, A Kitanaka, K Shimoda, K Morishita, Y Takihara, T Ichinohe
Journal: Blood Cancer Journal (2016)

All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors
Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder
Authors: Clemens W. Janssen, Christopher A. Lowry, Matthias R. Mehl, John J. B. Allen, Kimberly L. Kelly, Danielle E. Gartner, Angelica Medrano, Tommy K. Begay, Kelly Rentscher, Joshua J. White, Andrew Fridman, Levi J. Roberts, Megan L. Robbins, Kay-u Hanusch, Steven P. Cole, Charles L. Raison
Journal: JAMA Psychiatry (2016)

Limitations of current antidepressants highlight the need to identify novel treatments for major depressive disorder. A prior open trial found that a single session of whole-body hyperthermia (WBH) reduced depressive symptoms; however, the lack of a placebo control raises the possibility that the observed antidepressant effects resulted not from hyperthermia per se, but from nonspecific aspects of the intervention.To test whether WBH has specific antidepressant effects when compared with a sham condition and to evaluate the persistence of the antidepressant effects of a single treatment.A 6-week, randomized, double-blind study conducted between February 2013 and May 2015 at a university-based medical center comparing WBH with a sham condition. All research staff conducting screening and outcome procedures were blinded to randomization status. Of 338 individuals screened, 34 were randomized, 30 received a study intervention, and 29 provided at least 1 postintervention assessment and were included in a modified intent-to-treat efficacy analysis. Participants were medically healthy, aged 18 to 65 years, met criteria for major depressive disorder, were free of psychotropic medication use, and had a baseline 17-item Hamilton Depression Rating Scale score of 16 or greater.A single session of active WBH vs a sham condition matched for length of WBH that mimicked all aspects of WBH except intense heat.Between-group differences in postintervention Hamilton Depression Rating Scale scores.The mean (SD) age was 36.7 (15.2) years in the WBH group and 41.47 (12.54) years in the sham group. Immediately following the intervention, 10 participants (71.4%) randomized to sham treatment believed they had received WBH compared with 15 (93.8%) randomized to WBH. When compared with the sham group, the active WBH group showed significantly reduced Hamilton Depression Rating Scale scores across the 6-week postintervention study period (WBH vs sham; week 1: -6.53, 95% CI, -9.90 to -3.16, P < .001; week 2: -6.35, 95% CI, -9.95 to -2.74, P = .001; week 4: -4.50, 95% CI, -8.17 to -0.84, P = .02; and week 6: -4.27, 95% CI, -7.94 to -0.61, P = .02). These outcomes remained significant after evaluating potential moderating effects of between-group differences in baseline expectancy scores. Adverse events in both groups were generally mild.Whole-body hyperthermia holds promise as a safe, rapid-acting, antidepressant modality with a prolonged therapeutic benefit.clinicaltrials.gov Identifier: NCT01625546.
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry
Authors: Nicoletta Riva, Walter Ageno, Sam Schulman, Jan Beyer-Westendorf, Rita Duce, Alessandra Malato, Rita Santoro, Daniela Poli, Peter Verhamme, Ida Martinelli, Pieter Kamphuisen, Francesco Dentali
Journal: The Lancet Haematology (2016)
Carcinogenicity of Ethylmethanesulfonate
Authors: William Hrushesky, Derek Sampson, Gerald P. Murphy
Journal: JNCI Journal of the National Cancer Institute (1972)

Sprague-Dawley rats received 3 weekly intraperitoneal injections of 33 mg ethylmethanesulfonate (EMS). None of the control animals had tumors, but 53% of the treated animals developed malignant neoplasms, most of which were anaplastic lung lesions or adenocarcinomas of the abdominal wall, comparable to adenocarcinoma of the mammary gland. A striking sex difference in tumor incidence was observed: 74% in females and 34% in males. Sixty-five percent of the EMS-treated females developed adenocarcinoma by 12 months. No renal tumors were observed, and unilateral nephrectomy did not affect the incidence of neoplasms. No differences were observed in the serum erythropoietin levels between tumor-bearing and non-tumor-bearing animals. In view of the possible use of the monoesters of methanesulfonic acid as male contraceptive agents, the potent carcinogenicity of these substances in the rat should be considered.—J Natl Cancer Inst 49: 1077–1083, 1972.
Medicine, Money and Manpower — The Challenge to Professional Education
Authors: Ward Darley, Anne R. Somers
Journal: New England Journal of Medicine (1967)

MEDICINE and the other health professions have suddenly found themselves confronted by an array of formidable new challenges – particularly the challenges of affluence embodied in our $50,000,000,000 medical-care and research economy, of manpower shortages and of pervasive structural rigidities – all of which threaten to block the effective use of these new billions and the ever growing body of medical knowledge. The first article in this series attempted to document this hypothesis and to suggest the magnitude and nature of the challenge to professional education.In this installment we review recent developments in educational philosophy and theory that appear . . .
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury
Authors: Inmaculada Medina-Caliz, Mercedes Robles-Diaz, Beatriz Garcia-Muñoz, Camilla Stephens, Aida Ortega-Alonso, Miren Garcia-Cortes, Andres González-Jimenez, Judith A. Sanabria-Cabrera, Inmaculada Moreno, M. Carmen Fernandez, Manuel Romero-Gomez, Jose M. Navarro, Ana Mª Barriocanal, Eva Montane, Hacibe Hallal, Sonia Blanco, German Soriano, Eva M. Roman, Elena Gómez-Dominguez, Agustin Castiella, Eva M. Zapata, Miguel Jimenez-Perez, Jose M. Moreno, Ana Aldea-Perona, Manuel Hernández-Guerra, Martin Prieto, Miguel E. Zoubek, Neil Kaplowitz, M. Isabel Lucena, Raul J. Andrade
Journal: Journal of Hepatology (2016)
The Presence Of Spine Bone Plasmacytomas At The Time Of Multiple Myeloma (MM) Diagnosis Confers Poor Prognosis
Authors: Marie-Christine Kyrtsonis, Eftychia Nikolaou, Dimitrios Maltezas, Katerina Sarris, Efstathios Koulieris, Theodoros Iliakis, Nora Vyniou, Ioanna Vardounioti, Vassiliki Karali, Ilias Pessach, Vassiliki Bartzis, Tatiana Tzenou, Maria Dimou, Theodoros P. Vassilakopoulos, Maria K. Angelopoulou, Panagiotis Tsaftaridis, Irene Katodritou, Panayiotis Panayiotidis
Journal: Blood (2013)
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations
Authors: Jayasri G. Iyer, Kaushik Parvathaneni, Shailender Bhatia, Erica S. Tarabadkar, Astrid Blom, Ryan Doumani, Jill McKenzie, Maryam M. Asgari, Paul Nghiem
Journal: Journal of the American Academy of Dermatology (2016)
Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions
Authors: A. Desnoyer, N. Dupin, L. Assoumou, A. Carlotti, F. Gaudin, C. Deback, G. Peytavin, A.G. Marcelin, F. Boué, K. Balabanian, V. Pourcher
Journal: British Journal of Dermatology (2016)

Recent studies have independently implicated the chemokine CXCL12 and its receptors, CXCR4 and CXCR7, in the pathophysiology of Kaposi sarcoma (KS).We investigated whether the CXCL12/CXCR4-CXCR7 protein trio could constitute KS biomarkers.Endothelial and spindle cells positive for CXCL12/CXCR4-CXCR7, human herpesvirus-8 latency-associated nuclear antigen (LANA), Ki67 antigen (proliferation) and vascular endothelial growth factor (VEGF) were quantitated in skin lesions from patients with AIDS-associated KS, patients with classic KS and patients with angiomas, using immunohistochemistry and quantitative image analysis (16, 21 and 20 skin lesions, respectively). Plasma CXCL12 concentrations were measured by enzyme-linked immunosorbent assay from 20 patients with AIDS-KS, 12 HIV-infected patients without KS and 13 healthy donors' samples.Cells positive for CXCL12, CXCR4, CXCR7, LANA, Ki67 and VEGF were significantly enriched in patients with AIDS-associated KS and classic KS vs. angiomas (P < 0·001), and in nodular vs. macular/papular KS lesions (P < 0·05). CXCL12, CXCR4 and CXCR7 detection correlated with LANA, Ki67 and VEGF detection (r > 0·4; P < 0·05). However, plasma CXCL12 concentrations did not differ between patients with AIDS-associated KS, HIV-infected patients without KS, and healthy donors.The CXCL12/CXCR4-CXCR7 trio is upregulated in KS and correlates with KS pathophysiological markers and the severity of skin lesions. Histological assessment of the CXCL12 axis could serve as a valuable biomarker for KS diagnosis and progression.
Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
Authors: V Stefoni, B Casadei, C Bottelli, G Gaidano, C Ciochetto, M G Cabras, M Ansuinelli, L Argnani, A Broccoli, L Gandolfi, C Pellegrini, P L Zinzani
Journal: Blood Cancer Journal (2016)

An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell lymphoma patients were treated with (90)Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as long-term follow-up analyses of this combined therapeutic modality are lacking. The overall response rate to the entire regimen was 80%, including 73% (40/55) of complete response (CR) rate and 7% (4/55) of partial response rate. At the time of writing, 24/55 (43.6%) patients experienced a progression disease and 20 of 40 (50%) patients who obtained a CR are still alive in continuous CR. With a median follow-up of 7 years, the disease-free survival was 43.3% and the progression-free survival was 36.1%. The overall survival at 7.9 years was 38.9% (27 deaths mainly because of lymphoma). Two patients developed secondary hematological malignancies, an acute myeloid leukemia and a myelodysplastic syndrome, at 4 and 3 years from radioimmunotherapy, respectively. Our data confirm the feasibility, efficacy and safety of four cycles of R-CHOP followed by radioimmunotherapy consolidation even in the long term: this combination allows dispensing less chemotherapy in a frail group of patients without invalidating response quality and duration.
Decreased Resistance of C3H/HeHa Mice to C3HBA Tumor Transplants: Increased Resistance Due to Supplemental Vitamin A<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>
Authors: Eli Selfter, Ph.D., Giuseppe Retlura, Ph.D., Stanley M. Levenson, M.D.
Journal: JNCI Journal of the National Cancer Institute (1981)

Groups of inbred C3H/HeHa and C3H/HeJ mice were inoculated with either a low or a high number of C3HBA tumor cells, C3H/HeHa mice were less resistant to tumor development and growth than C3H/HeJ mice as judged by tumor incidence, latent period, tumor size (growth rate), and survival time. Resistance to decrease and death following inoculation with tumor cells was related to thymus status in the following way: Thymic involution was associated with decreased resistance of the mice to tumor development. When C3H/HeHa mice were fed supplemental vitamin A, and treatment that increases their thymus size and numbers of thymic small lymphocytes, their resistance to the C3HBA tumor was markedly increased.
Compartmentalization Is Key in Limiting Nitric Oxide Scavenging by Cell-Free Hemoglobin
Authors: Daniel B. Kim-Shapiro, Rakesh P. Patel
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

definitively proven, and no RCT of that size could definitively prove, that this therapy should not be considered in further RCTs.The growing array of RCTs of exercise interventions that demonstrate no difference contrasts sharply with the equally growing sense among clinicians that this is something that should be done.To advance, we need trials big enough to give either a compelling "yes" or a compelling "no" about specific timing and dose of rehabilitation in the ICU.As Popper argued, compelling refutation of hypotheses is essential for the advancement of science (15).
Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study
Authors: Jan Biegus, Hans L. Hillege, Douwe Postmus, Mattia. A.E. Valente, Daniel M. Bloomfield, John G.F. Cleland, Gad Cotter, Beth A. Davison, Howard C. Dittrich, Mona Fiuzat, Michael M. Givertz, Barry M. Massie, Marco Metra, John R. Teerlink, Adriaan A. Voors, Christopher M. O'Connor, Piotr Ponikowski
Journal: European Journal of Heart Failure (2016)
Liver Capsule: Biliary Tree Stem Cell Subpopulations
Authors: Domenico Alvaro, Eugenio Gaudio
Journal: Hepatology (2016)

1Department of Medico‐Surgical Sciences and Biotechnologies 2Anatomical, Histological, Forensic Medicine and Orthopedic SciencesSapienza, University of RomeRomeItaly * Corresponding author: [email protected]
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
Authors: X. Pivot, F. Marmé, R. Koenigsberg, M. Guo, E. Berrak, A. Wolfer
Journal: Annals of Oncology (2016)

Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic breast cancer (MBC) after ≥1 prior chemotherapy for advanced disease, including an anthracycline and a taxane in either the adjuvant or metastatic setting. Data from Studies 305 and 301 were pooled to investigate the efficacy of eribulin in various subgroups of patients who matched the EU label, including those with human epidermal growth factor receptor 2 (HER2)-negative and triple-negative disease.In Study 305 (NCT00388726), patients were randomized 2:1 to eribulin mesylate 1.4 mg/m(2) (equivalent to eribulin 1.23 mg/m(2) [expressed as free base]) intravenously on days 1 and 8 every 21 days] or treatment of physician's choice after 2-5 prior chemotherapies (≥2 for advanced disease), including an anthracycline and a taxane (in early/advanced setting). In Study 301 (NCT00337103), patients were randomized 1:1 to eribulin (as above) or capecitabine (1.25 g/m(2) orally twice daily on days 1-14 every 21 days) following ≤3 prior chemotherapies (≤2 for advanced disease), including an anthracycline and a taxane. Efficacy end points were investigated in the intent-to-treat population and subgroups, pooled as discussed above.Overall, 1644 patients were included (eribulin: 946; control: 698); baseline characteristics were well matched. Overall survival was significantly longer with eribulin versus control (P < 0.01), as were progression-free survival and clinical benefit rate (both P < 0.05). Significant survival benefits with eribulin versus control were observed in a wide range of patient subgroups, including HER2-negative or triple-negative disease (all P < 0.05).Our findings underline the survival benefit achieved by eribulin used according to EU label in the overall MBC population and in various subgroups of interest, including patients with HER2-negative and triple-negative disease.
Abstract 15027: Previous Therapy with Statins Reduces the Inflammatory Response in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Authors: Stefano Cornara, Alberto Somaschini, Rita Camporotondo, Gabriele Crimi, Andrea Baldo, Alessandra Repetto, Claudia Pavesi, Silvia Pica, Massimiliano Gnecchi, Gaetano M De Ferrari
Journal: Circulation (2014)

Background: Statins are known to possess anti-inflammatory properties in addition to their lipid lowering activity. Several inflammatory biomarkers including leukocyte (WBC) and neutrophil (Neutro) count and neutrophil to lymphocyte ratio (NLR) have been suggested as prognostic markers in patients with ST-elevation myocardial infarction (STEMI). Aim: Goal of this study was to investigate whether a previous therapy with statins influenced the inflammatory response of patients with STEMI. Methods: Consecutive patients undergoing primary percutaneous coronary intervention (pPCI) for STEMI in our Department from 2006 to 2012 (n=1271) were evaluated. We compared patients on statins at the time of STEMI (103; 8,1%) with the others. Inflammatory indexes were obtained by blood samples collected at hospital admission (T0) and the following day (T1). Results: Patients with previous statin-therapy were older (65 ± 12 vs 62 ± 13 years , p=0.007), had more frequently a previous MI (55% vs 8%, p&lt;0.001), hypertension (66% vs 52%, p=0.002), dyslipidemia (75% vs 35% p&lt;0.001), diabetes (25% vs 14%, p=0.002) and familiarity for cardiovascular diseases (44% vs 39%, p=0.01). They also showed a lower LV ejection fraction after PCI (42 ± 10% vs 45 ± 10% p=0.01) The inflammatory response in the two groups is shown in the Table. Previous statin-therapy was an independent predictor of all inflammatory markers at multivariable analysis. Conclusions: Previous statin-therapy at the time of STEMI reduces the inflammatory response, an effect associated with a better prognosis. Thus, treatment with statins in patients at risk not only reduces the incidence of MI but is likely to improve prognosis if a STEMI does occur.
DNA Labeling Index and Structure of the Rat Mammary Gland as Determinants of Its Susceptibility to Carcinogenesis&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: J Russo, I H Russo
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article DNA Labeling Index and Structure of the Rat Mammary Gland as Determinants of Its Susceptibility to Carcinogenesis Get access Jose Russo, Jose Russo 3Experimental Pathology Laboratory, Depanment of Biology, Michigan Cancer Foundation, 110 East Warren Ave., Detroit, Mich. 48201. Search for other works by this author on: Oxford Academic PubMed Google Scholar Irma H. Russo Irma H. Russo 3Experimental Pathology Laboratory, Depanment of Biology, Michigan Cancer Foundation, 110 East Warren Ave., Detroit, Mich. 48201. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 61, Issue 6, December 1978, Pages 1451–1459, https://doi.org/10.1093/jnci/61.6.1451 Published: 01 December 1978 Article history Received: 05 January 1978 Revision received: 23 June 1978 Accepted: 06 July 1978 Published: 01 December 1978